CAM
RCUS icon

Cresset Asset Management’s Arcus Biosciences RCUS Stock Holding History

Cresset Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34,848
Closed -$658K – 2161
2024
Q1 		$658K Buy
34,848
+634
+2% +$11K ﹤0.01% 1196
2023
Q4 		$653K Sell
34,214
-86
-0.3% -$1.37K ﹤0.01% 1086
2023
Q3 		$616K Sell
34,300
-833
-2% -$16.7K ﹤0.01% 1071
2023
Q2 		$714K Buy
+35,133
New +$669K ﹤0.01% 1091

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cresset Asset Management's RCUS Position: Q2 2024 in Review

Cresset Asset Management sold out of Arcus Biosciences (RCUS) in Q2 2024, closing a stake of 34,848 shares — an estimated $658K sold.

Cresset Asset Management first reported a position in RCUS in Q2 2023 and held it in 4 quarters. The position peaked at $714K in Q2 2023. 193 funds tracked by Wall St. Rank hold RCUS as of Q2 2024.

  • Cresset Asset Management reported no remaining Arcus Biosciences position as of Q2 2024 after selling out during the quarter.
  • Cresset Asset Management sold 34,848 Arcus Biosciences shares in Q2 2024, an estimated $658K.
  • Cresset Asset Management first reported a position in Arcus Biosciences in Q2 2023 and held it in 4 quarters.
  • Cresset Asset Management's Arcus Biosciences position peaked at $714K in Q2 2023.
  • 193 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2024.

Based on Cresset Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.